Cargando…

Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival

BACKGROUND AND AIMS: So far, no randomized trial or meta-analysis has been conducted on overall survival (OS) and recurrence-free survival (RFS) factors in patients treated with radiofrequency ablation (RFA) alone. The purpose of this meta-analysis was to evaluate prognostic factors of OS and RFS in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gardini, Andrea Casadei, Marisi, Giorgia, Canale, Matteo, Foschi, Francesco Giuseppe, Donati, Gabriele, Ercolani, Giorgio, Valgiusti, Martina, Passardi, Alessandro, Frassineti, Giovanni Luca, Scarpi, Emanuela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178942/ https://www.ncbi.nlm.nih.gov/pubmed/30323628 http://dx.doi.org/10.2147/OTT.S170836

Ejemplares similares

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Circulating Plasma Levels of miR-20b, miR-29b and miR-155 as Predictors of Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer
por: Ulivi, Paola, et al.
Publicado: (2018)

IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018)

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017)

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
por: Marisi, Giorgia, et al.
Publicado: (2018)

Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017)

Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study
por: Passardi, Alessandro, et al.
Publicado: (2019)

Erratum: Passardi, A. et al. Chemoradiotherapy (Gemox Plus Helical Tomotherapy) for Unresectable Locally Advanced Pancreatic Cancer: A Phase II Study. Cancers 2019, 11, 663
por: Passardi, Alessandro, et al.
Publicado: (2020)

Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic review
por: Gardini, Andrea Casadei, et al.
Publicado: (2017)

Prognostic role of a new inflammatory index with neutrophil-to-lymphocyte ratio and lactate dehydrogenase (CII: Colon Inflammatory Index) in patients with metastatic colorectal cancer: results from the randomized Italian Trial in Advanced Colorectal Cancer (ITACa) study
por: Casadei-Gardini, Andrea, et al.
Publicado: (2019)

Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study
por: Casadei Gardini, Andrea, et al.
Publicado: (2017)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Prognostic role of a new index (multi inflammatory index) in patients with metastatic colorectal cancer: results from the randomized ITACa trial
por: Casadei Gardini, Andrea, et al.
Publicado: (2020)

Prognostic role of serum concentrations of high-sensitivity C-reactive protein in patients with metastatic colorectal cancer: results from the ITACa trial
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin
por: De Matteis, Serena, et al.
Publicado: (2019)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Predictive role of multiple gene alterations in response to cetuximab in metastatic colorectal cancer: A single center study
por: Ulivi, Paola, et al.
Publicado: (2012)

Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial
por: Passardi, Alessandro, et al.
Publicado: (2017)

ANGPT2 and NOS3 Polymorphisms and Clinical Outcome in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib
por: Marisi, Giorgia, et al.
Publicado: (2019)

Paraneoplastic lipase and amylase production in a patient with small-cell lung cancer: case report
por: Casadei Gardini, Andrea, et al.
Publicado: (2016)

Neoadjuvant treatment (FOLFOX4 plus hypofractionated tomotherapy) for patients with locally advanced rectal cancer: a multicenter phase II trial
por: Passardi, Alessandro, et al.
Publicado: (2020)

Multimodal Treatment with GEMOX Plus Helical Tomotherapy in Unresectable Locally Advanced Pancreatic Cancer: A Pooled Analysis of Two Phase 2 Studies
por: Passardi, Alessandro, et al.
Publicado: (2021)

(1)H-NMR Based Serum Metabolomics Highlights Different Specific Biomarkers between Early and Advanced Hepatocellular Carcinoma Stages
por: Casadei-Gardini, Andrea, et al.
Publicado: (2020)

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
por: Rapposelli, Ilario Giovanni, et al.
Publicado: (2021)

Nomograms to Predict the Disease-free Survival and Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma
por: Takuma, Yoshitaka, et al.
Publicado: (2017)

Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials
por: Casadei Gardini, Andrea, et al.
Publicado: (2019)

Immune Checkpoints as a Target for Colorectal Cancer Treatment
por: Passardi, Alessandro, et al.
Publicado: (2017)

eNOS polymorphisms as predictors of efficacy of bevacizumab-based chemotherapy in metastatic colorectal cancer: data from a randomized clinical trial
por: Ulivi, Paola, et al.
Publicado: (2015)

Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC)
por: Casadei Gardini, Andrea, et al.
Publicado: (2014)

Recent Research on Gastrointestinal Carcinoma
por: Rovesti, Giulia, et al.
Publicado: (2021)

Cytoreduction plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in colorectal cancer patients: a single-center cohort study
por: Solaini, Leonardo, et al.
Publicado: (2019)

Pre-sarcopenia is the prognostic factor of overall survival in early-stage hepatoma patients undergoing radiofrequency ablation
por: Yeh, Wen-Shuo, et al.
Publicado: (2020)

Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma
por: Hur, Moon Haeng, et al.
Publicado: (2021)

Nomogram to Predict the Long-Term Overall Survival of Early-Stage Hepatocellular Carcinoma after Radiofrequency Ablation
por: Kuo, Yuan-Hung, et al.
Publicado: (2023)

Case Report: The Added Value of Liquid Biopsy in Advanced Colorectal Cancer From Clinical Case Experiences
por: Ulivi, Paola, et al.
Publicado: (2021)

Instability of Non-Standard Microsatellites in Relation to Prognosis in Metastatic Colorectal Cancer Patients
por: Pirini, Francesca, et al.
Publicado: (2020)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

EGFR methylation and outcome of patients with advanced colorectal cancer treated with cetuximab
por: CHIADINI, ELISA, et al.
Publicado: (2015)

Local Control by Radiofrequency Thermal Ablation Increased Overall Survival in Patients With Refractory Liver Metastases of Colorectal Cancer
por: Yang, Po-Chih, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_2e4c56m5s3jof78tbfkc287pd9